Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice TargetHot
Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.
Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.